{"id":847589,"date":"2025-05-06T16:23:21","date_gmt":"2025-05-06T20:23:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025\/"},"modified":"2025-05-06T16:23:21","modified_gmt":"2025-05-06T20:23:21","slug":"cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025\/","title":{"rendered":"Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NASHVILLE, Tenn.<\/span>
\n <\/span>, May 6, 2025<\/span><\/span> \/PRNewswire\/ — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)<\/b>, a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million<\/span> during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million<\/span> for the quarter, adjusted earnings of $2.4 million<\/span>, and cash flow from operations of $3.9 million<\/span>.<\/p>\n

\n

\n
\n \"Cumberland
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Cumberland<\/span> ended the quarter with approximately $70 million<\/span> in total assets, $41.6 million<\/span> in liabilities and $28.7 million<\/span> of shareholders’ equity.<\/p>\n

“We are entering an exciting time for our company, as we continue to build momentum and capitalize on a range of promising opportunities,” said Cumberland Pharmaceuticals CEO A.J. Kazimi<\/span>. “Our optimism is driven by strong performance from our approved brands, the expansion of international partnerships, meaningful progress across our clinical development programs and the potential for strategic acquisitions.”<\/p>\n

\n
\n RECENT COMPANY DEVELOPMENTS INCLUDE:<\/u>
\n <\/b>\n <\/p>\n

\n Top-Line DMD Study Results<\/b>\n <\/p>\n

In February 2025<\/span>, Cumberland<\/span> announced positive top-line results from the Phase II study evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (DMD). This marks a breakthrough for these patients, as it’s the first successful Phase II study specifically targeting the cardiac complications of their condition.<\/p>\n

These study results were selected for a late-breaking presentation in March at the Muscular Dystrophy Association<\/i>‘s Clinical & Scientific Conference<\/i>.\u00a0 That platform allowed Cumberland<\/span> to share the promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease.<\/p>\n

Next steps for Cumberland’s<\/span> DMD program include further data analysis and completion of a full study report in preparation for an end-of-Phase-II meeting with the FDA to determine the requirements for the product’s approval.<\/p>\n

\n Vibativ\u00ae<\/sup> Approval in China<\/span><\/b>\n <\/p>\n

\n Cumberland’s<\/span> potent antibiotic, Vibativ\u00ae<\/sup><\/b>, received approval from the regulatory authorities in China<\/span>. This provides Cumberland<\/span> access to the world’s second-largest pharmaceutical market. The company expects the product to launch by the end of the year.<\/p>\n

\n
\n FINANCIAL RESULTS:<\/u>
\n <\/b>\n <\/p>\n

\n Net Revenue: <\/b>For first quarter of 2025, net revenues were $11.7 million<\/span> and included $3.5 million<\/span> for Kristalose\u00ae<\/sup>, $2.3 million<\/span> for Sancuso\u00ae<\/sup>, $1.4 million<\/span> for Vibativ\u00ae <\/sup>and $1.3 million<\/span> for Caldolor\u00ae<\/sup>.<\/p>\n

\n Operating Expenses:<\/b> Total operating expenses for the quarter were $10.4 million<\/span>.<\/p>\n

\n Net Income:<\/b> The net income for the first quarter of 2025 was approximately $1.3 million<\/span>.<\/p>\n

\n Adjusted Earnings: <\/b>Adjusted earnings for the quarter were $2.4 million<\/span>, or $0.16<\/span> per share.<\/p>\n

\n Balance Sheet:<\/b> At March 31, 2025<\/span>, Cumberland<\/span> had approximately $70 million<\/span> in total assets, including $15.1 million<\/span> in cash and cash equivalents. Liabilities totaled $41.6 million<\/span>, including $5.2 million<\/span> on the company’s credit facility. Total shareholders’ equity was $28.7 million<\/span> on March 31, 2025<\/span>.<\/p>\n

\n
\n EARNINGS REPORT CALL:<\/u>
\n <\/b>\n <\/p>\n

A conference call will be held today, May 06, 2025<\/span>, at 4:30 p.m. Eastern Time<\/span> to provide a company update and discuss the financial results.<\/p>\n

The link to register is: https:\/\/register-conf.media-server.com\/register\/BIea2bc7f82dd24caea135dbe5460d9b6f<\/a><\/u>.\u00a0<\/p>\n

Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a “Call Me” option to have the system automatically call them at the start of the conference.<\/p>\n

A replay of the call will be available for one year and can be accessed via Cumberland’s<\/span> website or by visiting:<\/p>\n

\n
\n https:\/\/edge.media-server.com\/mmc\/p\/wost2na9\/<\/a>.<\/u>\n <\/p>\n

\n ABOUT CUMBERLAND<\/span> PHARMACEUTICALS:<\/b>\n <\/p>\n

\n Cumberland Pharmaceuticals Inc.<\/b> is the largest biopharmaceutical company founded and headquartered in Tennessee<\/span> and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company’s portfolio of FDA-approved brands includes:<\/p>\n